



RECEIVED

JUL 07 2003

#13

Sheet 1 of 1

TECH CENTER 1600/2900

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
294-120 PCT/USSERIAL NO.
10/049,473APPLICANT
de Groot, et al.CONFIRMATION NO.
4102FILING DATE
July 30, 2002GROUP
1645

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		WO 00/06737	2/20/00	PCT WO				
		WO 98/18930	5/7/98	PCT WO				
		WO 97/37026	10/9/97	PCT WO				

RECEIVED
JUL 07 2003

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1.	Jansen, W.T.M., et al., "Use of Highly Encapsulated <i>Streptococcus pneumoniae</i> Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specific Antibodies", <i>Clinical and Diagnostic Laboratory Immunology</i> Sept. 1998, 5(5):703-710.
		2.	McDaniel, Larry S., et al., "Comparison of the PspA Sequence from <i>Streptococcus pneumoniae</i> EF5668 to the Previously Identified PspA Sequence from Strain Rx1 and Ability of PspA from EF5668 to Elicit Protection against Pneumococci of Different Capsular Types", <i>Infection and Immunity</i> Oct. 1998, 66(10):4748-4754.
		3.	Overweg, K., et al., "The Putative Proteinase Maturation Protein A of <i>Streptococcus pneumoniae</i> is a Conserved Surface Protein with Potential to Elicit Protective Immune Responses", <i>Infection and Immunity</i> 2000, 68(7):4180-4188.

175044_1

EXAMINER

DATE CONSIDERED

10/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.